Education
About Us
Working with TipRanks
Follow Us
Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
CU6 Stock Chart & Stats
AU$2.86
-AU$0.24(-5.69%)
At close: 4:00 PM EST
AU$2.86
-AU$0.24(-5.69%)
Day’s Range― - ―
52-Week RangeAU$1.43 - AU$5.87
Previous CloseN/A
Volume1.66M
Average Volume (3M)3.27M
Market Cap
AU$1.06B
Enterprise ValueAU$1.02B
Total Cash (Recent Filing)AU$84.12M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Mar 04, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding372,030,060
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$5.70Price Target Upside99.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure meaningfully lowers financing risk and interest burden for a clinical-stage biotech. This durable strength increases strategic optionality for funding clinical programs and partnerships, reducing near-term solvency pressure while cash burn persists.
Focused Theranostics FranchiseA focused business model in oncology theranostics targets a high-barrier niche with technical IP and specialized regulatory pathways. This structural specialization can create durable competitive advantages, enabling differentiated products and partnership value as clinical data matures.
Prior Multi-year Revenue GrowthHistoric multi-year revenue expansion indicates the company previously scaled aspects of its business or commercial outreach. That underlying capacity to grow revenue is a durable operational strength, even if recent setbacks require management to restore momentum.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing cash consumption from operations and trials, forcing reliance on external financing or partnerships. Over months this elevates dilution and execution risk, and constrains the ability to fund clinical milestones internally.
Widening Losses / Weak ProfitabilityDeep and worsening losses reflect operating expenses far outstripping revenue, limiting reinvestment flexibility and signaling that current commercial or R&D returns are insufficient. This structural profitability weakness raises questions on sustainable path to positive earnings.
Declining Equity BaseA shrinking equity base is a durable balance-sheet concern: it reflects accumulated losses and reduces financial cushions against shocks. Persisting declines increase the likelihood and potential size of future equity raises, diluting existing holders and impacting long-term capital structure.
Clarity Pharmaceuticals Ltd. News
CU6 FAQ
What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?
Clarity Pharmaceuticals Ltd. lowest share price was AU$1.43 and its highest was AU$5.87 in the past 12 months.
What is Clarity Pharmaceuticals Ltd.’s market cap?
Clarity Pharmaceuticals Ltd.’s market cap is AU$1.06B.
When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?
Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 15 days.
How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?
Clarity Pharmaceuticals Ltd. released its earnings results on Aug 28, 2025. The company reported -AU$0.12 earnings per share for the quarter, missing the consensus estimate of -AU$0.079 by -AU$0.041.
Is Clarity Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Clarity Pharmaceuticals Ltd. pay dividends?
Clarity Pharmaceuticals Ltd. does not currently pay dividends.
What is Clarity Pharmaceuticals Ltd.’s EPS estimate?
Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.08.
How many shares outstanding does Clarity Pharmaceuticals Ltd. have?
Clarity Pharmaceuticals Ltd. has 372,030,060 shares outstanding.
What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?
Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.12 in its last earnings report, missing expectations of -AU$0.079. Following the earnings report the stock price went down -7.558%.
Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:CU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clarity Pharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$5.70 (99.30% Upside)
AU$5.70 (99.30% Upside)
Blogger Sentiment
Bullish
AU:CU6 Sentiment 91%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
-54.37%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
CU6 Stock 12 Month Forecast
Average Price Target
AU$5.70
▲(99.30% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Telix Pharmaceuticals
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---